Ziihera bags a gastric win
But Enhertu is coming.
Amgen goes pivotal with subcutaneous Blincyto
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
Pfizer speeds ahead with bispecific development
The company will imminently start its third pivotal trial of PF-08634404.
Lorikeet fails to fly for MacroGenics
The company ditches lorigerlimab in prostate cancer.
Immatics’ PRAME T-cell engager improves
The response rate jumps to 30% with higher doses of IMA402.
Gastrointestinal is next for pumitamig
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
ESMO 2025 – J&J brings a new Rybrevant use into the fold
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
J&J claims a Tecvayli/Darzalex combo win
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
Astra pulls further ahead of Merck’s Curon project
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
